Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms

BACKGROUND: Pioglitazone (PIO), a thiazolidinediones drug, is a well-known anti-diabetic medicine, but its anti-atherosclerotic effects remain controversial. Thus it is important to investigate the effects of PIO on atherogenesis and the relevant mechanisms. METHODS: For in vitro studies, primary cu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Diabetol
Main Authors: Tian, Yuling, Chen, Tao, Wu, Yan, Yang, Lin, Wang, Lijun, Fan, Xiaojuan, Zhang, Wei, Feng, Jiahao, Yu, Hang, Yang, Yanjie, Zhou, Juan, Yuan, Zuyi, Wu, Yue
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5663071/
https://ncbi.nlm.nih.gov/pubmed/29084546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-017-0623-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados